KT-333 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Natural Killer Cell Lymphomas. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of KT-333’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for KT-333 is expected to reach an annual total of $124 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
KT-333 Overview
KT-333 is under development for the treatment of peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma (CTCL), large granular lymphocytic leukemia (LGL-L), Hodgkin lymphoma, small lymphocytic lymphoma (SLL), non-Hodgkin Lymphoma, natural killer cell lymphomas, T-cell lymphomas and solid tumors like colorectal cancer and non-small cell lung cancer. The drug candidate is a heterobifunctional PROTAC (proteolysis targeting chimera) which acts by degrading STAT3. It is developed based on Pegasus platform.
Kymera Therapeutics Overview
Kymera Therapeutics (Kymera) is a clinical stage biopharma and technology company involved in developing small molecule therapeutics for protein degradation. The companiy’s pipeline product portfolio comprise IRAK4, IRAKIMiD, STAT3 and MDM2. Its targeted protein degradation platform Pegasus, an information technology powered platform that allows the discovery of selective small molecule protein degraders against disease-causing proteins throughout the body. The company also carries out research and discovery of breakthrough drugs addressing novel medical areas. Its product find application in cancers, inflammatory, autoimmune and other related diseases. Kymera is headquartered in Watertown, Massachusetts, the US.
The company reported revenues of (US Dollars) US$72.8 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$34 million in FY2020. The operating loss of the company was US$100.5 million in FY2021, compared to an operating loss of US$46.3 million in FY2020. The net loss of the company was US$100.2 million in FY2021, compared to a net loss of US$45.6 million in FY2020.
The company reported revenues of US$9.6 million for the third quarter ended September 2022, a decrease of 17% over the previous quarter.
For a complete picture of KT-333’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
